Discover a study validating a disease-specific quality-of-life tool for hidradenitis suppurativa, confirming its reliability, ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...

Hidradenitis suppurativa patients face higher depression and anxiety risks, but biologic treatments may reduce these mental ...

We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we ...

Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

Explore how hidradenitis suppurativa is linked to increased rates of depression and anxiety, with no clear connection to ...

UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a ...

Hidradenitis suppurativa is exceptionally underdiagnosed, with delays in diagnosis of 10 years on average and most patients seeking care more than 5 times before receiving the diagnosis. These ...

ZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for ...